Comparison of the efficacy and adverse effects of visipaque and Ultravist in Contrast-enhanced CT Sca
Not Applicable
- Conditions
- All of patients referred to abdominal and pelvic CT.
- Registration Number
- IRCT138904144316N1
- Lead Sponsor
- Vice chancellor for research, Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Inclusion criteria : patients reffered for abdomenoplevic CT
Exclusion criteria : renal disease, Diabetes, known drug reaction
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increasing of contrast enhancement. Timepoint: 60 seconds after injection. Method of measurement: dansitometry with CTscan appratus.
- Secondary Outcome Measures
Name Time Method Complication post injection. Timepoint: To one week after injection. Method of measurement: registrationin questionare.